DuPont de Nemours, Inc. reported first‑quarter 2026 results on May 5 2026, delivering net sales of $1.681 billion and adjusted earnings per share of $0.55. The company’s adjusted EPS fell from $1.03 in the same quarter of 2025, reflecting a sharp decline in top‑line revenue that dropped from $3.1 billion to $1.681 billion year‑over‑year.
Organic sales grew 2% in the quarter, a deceleration from the 6% growth seen in Q1 2025. The modest organic growth was driven by a 3% increase in the Healthcare & Water Technologies segment, while other segments, particularly Diversified Industrials, experienced softness. The company’s operating EBITDA rose to $414 million, a 15% increase from the prior quarter, and the operating EBITDA margin expanded by 110 basis points, largely due to a favorable product mix and productivity gains.
DuPont raised its full‑year 2026 guidance, projecting net sales of $7.155 billion to $7.215 billion and adjusted EPS of $2.35 to $2.40, up from the previous range of $2.25 to $2.30. Management cited a strong start to the year and the interest‑income benefit from the Aramids divestiture as key reasons for the upward revision. The company also announced a $275 million accelerated share‑repurchase program to support shareholder value.
The earnings beat analysts’ consensus estimate of $0.48 per share by $0.07, a 15% outperformance. The beat was driven by disciplined cost control and a shift toward higher‑margin products, which helped offset the revenue decline. Margin expansion, driven by mix and productivity, further bolstered profitability. The guidance increase signals management’s confidence in sustaining growth momentum despite the revenue contraction, while the share‑repurchase program underscores a commitment to returning capital to shareholders.
"We delivered a strong start to the year, exceeding our financial guidance through disciplined commercial and operational execution. Our teams remained focused on our customers and delivered organic growth, margin expansion, and double‑digit adjusted EPS growth, along with solid cash flow generation in the quarter," said CEO Lori Koch. CFO Antonella Franzen added, "We are raising our full year 2026 guidance given our strong start to the year and the interest income benefit from the Aramids transaction. In addition, our full year net sales guidance now assumes about 4% organic growth including about 1% of pricing due to actions taken to fully offset higher input costs related to the Middle East conflict."
The market reacted positively to the earnings beat, guidance raise, margin expansion, and the completion of the Aramids divestiture, all of which reinforced investor confidence in DuPont’s execution and capital allocation strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.